October 20, 2020

Tocilizumab for Treating COVID-19: A Systemic Review and Meta-Analysis of Retrospective Studies

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• A systematic review of case-control (n=2,285 patients) and single-arm studies (n=208 patients) found that treatment with the immunomodulator tocilizumab (TCZ) in COVID-19 patients was associated with a lower risk of admission to ICU, invasive ventilation, and mortality compared with standard treatment. Patients who received TCZ had changes of several clinical indicators that marked higher rates of clinical improvement.

Zhao et al. (Oct 13, 2020). Tocilizumab for Treating COVID-19: A Systemic Review and Meta-Analysis of Retrospective Studies. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-020-03017-5